Fulcrum Therapeutics, Inc.
NASDAQ Global MarketTotal Valuation
Fulcrum Therapeutics, Inc. carries a market capitalization of 281.92M, placing it among publicly traded companies globally. Its enterprise value stands at -34.36M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 281.92M |
| Enterprise Value | -34.36M |
Share Statistics
Fulcrum Therapeutics, Inc. currently has 76.29M shares outstanding.
| Shares Outstanding | 76.29M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 0.90 |
| P/TBV Ratio | 0.90 |
| P/FCF Ratio | -3.93 |
| P/OCF Ratio | -3.91 |
Financial Position
Fulcrum Therapeutics, Inc. maintains a current ratio of 31.35, meaning it holds 31.4x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 31.35 |
| Quick Ratio | 31.16 |
| Debt / Equity | 1.70 |
| Debt / EBITDA | -0.06 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -32.38 |
| Return on Assets (ROA) | -30.75 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Fulcrum Therapeutics, Inc.'s stock has declined approximately -59.92408% over the past 52 weeks. The 50-day moving average sits at 3.78, while the 200-day moving average is 6.16.
| Beta (5Y) | N/A |
| 52-Week Price Change | -59.92408% |
| 50-Day Moving Average | 3.78 |
| 200-Day Moving Average | 6.16 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -85.40M, while operating income came in at -86.64M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -86.64M |
| Pretax Income | -85.00M |
| Net Income | -85.00M |
| EBITDA | -85.40M |
| EBIT | -86.64M |
| Earnings Per Share (EPS) | -1.21 |
Balance Sheet
Fulcrum Therapeutics, Inc. holds 318.84M in cash and equivalents against 5.28M in total debt, resulting in a net debt position of -48.47M. Total book value stands at 310.70M, with working capital of 312.55M providing operational flexibility.
| Cash & Cash Equivalents | 318.84M |
| Total Debt | 5.28M |
| Net Debt | -48.47M |
| Equity (Book Value) | 310.70M |
| Book Value Per Share | 4.07 |
| Working Capital | 312.55M |
Cash Flow
Fulcrum Therapeutics, Inc. produced -65.78M in operating cash flow over the past twelve months. After subtracting -365,000.00 in capital expenditures, free cash flow totaled -66.14M - equivalent to -0.94 per share.
| Operating Cash Flow | -65.78M |
| Capital Expenditures | -365,000.00 |
| Free Cash Flow | -66.14M |
| FCF Per Share | -0.94 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -60.32 |
| FCF Yield | -25.45 |
Scores
Fulcrum Therapeutics, Inc. posts an Altman Z-Score of 10.15, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 10.15 |